Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CES1 | P23141 | 2/20 | 0.38 |
| ▸ | ACLY | P53396 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.31 |
| ▸ | LCK | P06239 | 1/20 | 0.31 |
| ▸ | FYN | P06241 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL474 | 1.00 | — | — | |
| Trifluoroacetic Acid SCHEMBL4598430 | 1.00 | — | — | |
| Trifluoroacetic Acid SCHEMBL30657022 | 1.00 | — | — | |
| Trifluoroacetic Acid SCHEMBL7814389 | 1.00 | ALDH1A1 (0.44) | ALDH1A1L3MBTL1TSHRTP53THRB | |
| Trifluoroacetic Acid SCHEMBL25297651 | 0.95 | ALDH1A1 (0.42) | ALDH1A1L3MBTL1TSHRTP53THRB | |
| Trifluoroacetic Acid SCHEMBL20571142 | 0.95 | — | — | |
| Trifluoroacetic Acid SCHEMBL901584 | 0.95 | — | — | |
| Trifluoroacetic Acid SCHEMBL21802705 | 0.95 | ALDH1A1 (0.42) | ALDH1A1L3MBTL1TSHRTP53THRB | |
| Trifluoroacetic Acid SCHEMBL22712611 | 0.95 | — | — | |
| Trifluoroacetic Acid SCHEMBL20541014 | 0.95 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 235 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12516050-B2 | Method for preparing isavuconazonium sulfate | SHANGHAI DESANO BIO-PHARMACEUTICAL CO., LTD. (CN) | 2026-01-06 | — | — | US | claimed |
| WO-2025111563-A1 | MILK PEPTIDE COMPOSITIONS FOR PHARMACEUTICAL AND COSMECEUTICAL USE | MATRUBIALS INC. (US) | 2025-05-30 | — | — | WO | claimed |
| CN-116496358-A | Preparation method of in vivo escape carrier cyclic peptide (CP-1) | 南京盛肽医药科技有限公司 | 2023-07-28 | — | — | CN | claimed |
| US-20230075632-A1 | METHOD FOR PREPARING ISAVUCONAZONIUM SULFATE | SHANGHAI DESANO PHARMACEUTICALS CO., LTD. (CN) | 2023-03-09 | — | — | US | claimed |
| EP-4083039-A1 | METHOD FOR PREPARING ISAVUCONAZONIUM SULFATE | Shanghai Desano Bio-Pharmaceutical Co., Ltd. (CN) | 2022-11-02 | — | — | EP | claimed |
| EP-3817759-A1 | A RECONSTITUTABLE TEVERELIX-TFA COMPOSITION | Antev Limited (GB) | 2021-05-12 | — | — | EP | claimed |
| CN-107406440-B | BACE1 inhibitors | 豪夫迈·罗氏有限公司 | 2021-05-07 | — | — | CN | claimed |
| US-20200308166-A1 | BACE1 INHIBITORS | HOFFMANN-LA ROCHE INC. | 2020-10-01 | — | — | US | claimed |
| WO-2020007852-A1 | A RECONSTITUTABLE TEVERELIX-TFA COMPOSITION | ANTEV LIMITED (GB) | 2020-01-09 | — | — | WO | claimed |
| US-10399969-B2 | BACE1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2019-09-03 | — | — | US | claimed |
| CN-103201280-B | The compositions of suppression JAK approach and method | 里格尔药品股份有限公司 | 2016-08-10 | — | — | CN | claimed |
| CN-103201280-A | Compositions and methods for inhibition of the jak pathway | RIGEL PHARMACEUTICALS INC | 2013-07-10 | — | — | CN | claimed |
| EP-1827439-A2 | NOVEL M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2007-09-05 | — | — | EP | claimed |
| WO-2006055503-A2 | NOVEL M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2006-05-26 | — | — | WO | claimed |
| EP-1265867-B1 | MALONIC ACID DERIVATES, PROCESSES FOR THEIR PREPARATION, THEIR USE AS INHIBITOR OF FACTOR XA ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI AVENTIS DEUTSCHLAND (DE) | 2005-12-28 | — | — | EP | claimed |
| US-6794365-B2 | INHIBITORS OF THE BLOOD CLOTTING ENZYME FACTOR XA; TREATING THROMBOEMBOLIC DISEASES; TRIFLUOROACETIC ACID SALT OF 2-(4-CARBAMIMIDOYL-BENZYL)-N-((1-CARBAMOYL-4-GUANIDINO-BUTYLCARBAMOYL) -CYCLOHEXYL-METHYL)-N',N'-DIMETHYL-MALONAMIDE | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-09-21 | — | — | US | claimed |
| EP-1265867-A1 | NOVEL MALONIC ACID DERIVATES, PROCESSES FOR THEIR PREPARATION, THEIR USE AS INHIBITOR OF FACTOR XA ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Aventis Pharma Deutschland GmbH (DE) | 2002-12-18 | — | — | EP | claimed |
| US-20020022596-A1 | Novel malonic acid derivatives, processes for their preparation their use and pharmaceutical compositions containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-02-21 | — | — | US | claimed |
| WO-2001062735-A1 | NOVEL MALONIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION, THEIR USE AS INHIBITOR OF FACTOR XA ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-08-30 | — | — | WO | claimed |
| EP-1127884-A1 | Novel malonic acid derivatives, processes for their preparation, their use as inhibitor of factor XA activity and pharmaceutical compositions containing them | Aventis Pharma Deutschland GmbH (DE) | 2001-08-29 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230075632-A1 | METHOD FOR PREPARING ISAVUCONAZONIUM SULFATE | STS, MPST, ARSA | ALDH1A1 1511/4885L3MBTL1 4872/4885TSHR 3995/4885 |
| US-10399969-B2 | BACE1 inhibitors | BACE1, BACE2, APP | ALDH1A1 788/4885L3MBTL1 3525/4885TSHR 4825/4885 |
| US-20020022596-A1 | Novel malonic acid derivatives, processes for their preparation their use and pharmaceutical compositions containing them | F12, ME1, F11 | ALDH1A1 129/4885L3MBTL1 2204/4885TSHR 3149/4885 |
| US-20200308166-A1 | BACE1 INHIBITORS | BACE1, BACE2, APP | ALDH1A1 788/4885L3MBTL1 3525/4885TSHR 4825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.